Genes Are Not The Only Drivers Of Colon Cancer

Key points
- A new study suggests cellular factors play an equally important part, and these not only drive tumor growth, but also affect how well the disease responds to chemotherapy.
- For their study, Dick and colleagues found a way to follow single tumor cells as they developed with time.
- Dick and colleagues then tested the effect of chemotherapy on the human tumors growing in the immune-deficient mice.
- The findings challenge the conventional view that tumor growth and chemotherapy resistance are governed purely by the genetic mutations in the cells of the tumor.
Genes are not the only drivers of colon cancer. A new study suggests cellular factors play an equally important part, and these not only drive tumor growth, but also affect how well the disease responds to chemotherapy.
Senior study author John Dick, of the Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, and colleagues, write about their findings in a paper published online in Science on Thursday.
Using lab-bred mice with poor immune systems to grow human colorectal cancers, they found biological factors and cell behavior, not just genes, drove tumor growth and contributed to treatment failure and relapse.
Dick, who is also a Professor in the Department of Molecular Genetics at the University of Toronto, says in a press statement that the study represents a "a major conceptual advance in understanding tumor growth and treatment response".
Not All Cancer Cells are Equal
For their study, Dick and colleagues found a way to follow single tumor cells as they developed with time.
They discovered that not all cancer cells are equal. Only some keep the cancer growing, and within this group, there are further differences: for instance some cells drove growth for long periods, up to 500 days, while others stopped after 100 days.
They also found a class of cancer-driving cells that lies dormant before being activated.
And they were surprised to discover that the mutated genes were the same for all the different cell behaviors.
Cells Responded Differently to Chemo
Dick and colleagues then tested the effect of chemotherapy on the human tumors growing in the immune-deficient mice.
They found that the treatment generally killed off the longer-term tumor-driving cells.
But unexpectedly, instead of killing the shorter-term tumor-driving cells, chemotherapy brought them out of their dormant state into an active state, causing tumors to grow again.
And again, the researchers found the tumor-driving cells that survived had the same mutations as the ones killed off by the treatment.
They say this proves it was cellular factors and not genetic mutation that was responsible for treatment failure.
"Paradigm Shift" Challenges Conventional View
The findings challenge the conventional view that tumor growth and chemotherapy resistance are governed purely by the genetic mutations in the cells of the tumor.
"The data show that gene sequencing of tumours to find the spectrum of their mutations is definitely not the whole story when it comes to determining which therapies will be most effective," says Dick.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsColon cancer screening guidelines may miss 10 percent of colon cancers
For people with a family history of adenomas (colon polyps that lead to colon cancer), up to 10 percent of colorectal cancers could be missed when current national screening guidelines are followed. Colorectal cancer is…
23 October 2013
NewsMinimally invasive operation helps elderly patients after colon cancer treatment
The chance of ending up in a nursing facility appears to be significantly lower for older patients who undergo a laparoscopic procedure than for those who have open surgical resection for colon cancer, according to a…
9 October 2013
NewsStudies confirm colon cancer screening reduces deaths
There's new evidence that regular screening for colon cancer has long-term benefits. Testing for blood in the stool reduced the risk of death from colorectal cancer by as much as 32 percent and it seemed to keep the…



